No quarterly revenue total was found in CYTODYN INC.'s SEC filings.
Cytodyn Inc. (CYDY) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Aug 31, 2026 it held $16.4 million in cash and investments and $35.9 million in total debt.
Revenue
—
Net income
$-19.94M
-259.9% vs year-ago quarter
Operating cash flow
$-7.73M
-215.3% vs year-ago quarter
Free cash flow
—
EPS
$-0.01
Dividend per share
None
Shares outstanding
1.47B
+16.7% vs year-ago quarter
Net cash
$-19.52M
Q1 FY2027
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CYDY (OTC)
- Fiscal year ends
- May 31
- Incorporated in
- DE
- Headquarters
- Vancouver, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1175680
- Former names
- CYTODYN INC (until Apr 13, 2016); REXRAY CORP (until Nov 12, 2003)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q1 FY2027 Aug 31, 2026 |
Q4 FY2026 May 31, 2026 |
Q3 FY2026 Feb 28, 2026 |
Q2 FY2026 Nov 30, 2025 |
Q1 FY2026 Aug 31, 2025 |
|---|---|---|---|---|---|
| Operating income | -$6.6M | -$5.6M | -$6.3M | -$21.7M | -$4.9M |
| Net income | -$19.9M | -$9.9M | -$4.7M | -$22.6M | -$5.5M |
| Diluted EPS | -$0.01 | -$0.01 | $0.00 | -$0.02 | $0.00 |
| Operating cash flow | -$7.7M | -$4.9M | -$5.5M | -$4.3M | -$2.5M |
| Total assets | $19.1M | $14.0M | $18.5M | $8.9M | $13.5M |
| Total liabilities | $117.1M | $123.7M | $122.8M | $128.7M | $113.0M |
| Stockholders' equity | -$98.1M | -$109.7M | -$104.3M | -$119.7M | -$99.5M |
| Cash and investments | $16.4M | $11.9M | $15.7M | $5.0M | $9.3M |
| Total debt | $35.9M | $38.4M | $40.6M | $42.2M | $43.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 19, 2026 | Oct 16, 2026 |
| 10-Q | Quarterly report | Oct 14, 2026 | Aug 31, 2026 |
| 10-K | Annual report | Aug 31, 2026 | May 31, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 30, 2026 | Apr 30, 2026 |
| 10-Q | Quarterly report | Apr 8, 2026 | Feb 28, 2026 |
| 8-K |
Current report
Material agreement
|
Mar 24, 2026 | Mar 24, 2026 |
All 1001 Cytodyn Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.